Validation of a miRNA biomarker signature for early detection of lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031791

Enrollment

360

Registered

2023-05-12

Start date

2019-03-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34.1

Interventions

Group 1: Patients diagnosed with lung cancer (evaluation of preserved patient samples from a biobank.) Group 2: Patients without lung cancer (evaluation of preserved patient samples from a biobank.)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Presence of appropriate sample materials (here PAXgene tubes) in Biobank for miRNA analysis.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The aim of this study is to evaluate a novel miRNA-based method for early detection of lung cancer (NSCLC) in a cohort of patients with suspicious X-ray/CT findings. In this study, 360 preserved patient samples will be selected from a biobank.	—

Secondary

Measure	Time frame
The existing miRNA signature will applied to these samples and the sensitivity as well as specificity will be determined.	—

Countries

Germany

Contacts

Public ContactThomas Muley

Thoraxklinik Heidelberg

Thomas.Muley@med.uni-heidelberg.de+49 6221 396 1110

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026